Isavuconazole Shows Promise for Invasive Aspergillosis
The Wall Street Journal have reported that Astellas, developer of a new antifungal drug isavuconazole, have published some results from their phase III trials on the treatment of invasive aspergillosis that show its promise in comparison to voriconazole.
In particular in a sample of 500 patients there was 7% lower mortality and only 40% drug related adverse events with isavuconazole versus 60
0 Response to "Isavuconazole Shows Promise for Invasive Aspergillosis"
Post a Comment